ENJAYMO

Peak

sutimlimab-jome

Recordati
BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

Classical Complement Pathway Inhibitors

Pharmacologic Class:

Classical Complement Pathway Inhibitor

Indications (1)

hemolysis in adults with cold agglutinin disease (CAD)
Company
Recordati
Recordati
France - Saint-Victor
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers